Revenue

Refer to Note 2: Summary of Significant Accounting Policies and Note 7: Contract Balances for a complete description of our revenue recognition policy under ASC 606, as well as comparative information demonstrating the impact of ASC 606 on our consolidated financial statements.

We disaggregate our revenue from contracts with customers by type of service, as we believe this best depicts how the nature, amount, timing, and uncertainty of our revenue and cash flows are affected by economic factors. The following tables present our revenue disaggregated by type of service.

By Service Offering – Third Party:

	Three Months Ended June 30,				Six Months Ended June 30,
		2018		2017		2018		2017
Clinical sample profiling services	$	20,709	$	11,977	$	36,298	$	22,626
Pharma sample profiling services		15,746		10,697		28,852		13,151
Other molecular information services		2,247		2,103		5,328		4,594
Total molecular information services		38,702		24,777		70,478		40,371
R&D and regulatory services		3,732		1,215		8,514		2,302
Total pharma research and development services		3,732		1,215		8,514		2,302
Total revenue	$	42,434	$	25,992	$	78,992	$	42,673

By Service Offering – Related Party:

	Three Months Ended June 30,				Six Months Ended June 30,
		2018		2017		2018		2017
Clinical sample profiling services	$	3,089	$	964	$	6,287	$	1,934
Pharma sample profiling services		6,277		3,556		16,727		7,090
Other molecular information services		2,639		1,000		3,806		2,000
Total molecular information services		12,005		5,520		26,820		11,024
R&D and regulatory services		2,567		3,492		4,034		7,635
Total pharma research and development services		2,567		3,492		4,034		7,635
Total revenue	$	14,572	$	9,012	$	30,854	$	18,659

On June 30, 2018, we had $138.6 million of remaining transaction price allocated to performance obligations which are unsatisfied or partially unsatisfied, of which $57.4 million is associated with related parties. For the $57.4 million associated with related parties, we expect to recognize approximately 64 percent of our remaining transaction price as revenue within the next 12 months following June 30, 2018 and an additional 34 percent in the 12 months thereafter, and the remaining 2 percent thereafter. For the remaining $81.2 million, we expect to recognize approximately 39 percent of our remaining transaction price as revenue within the next 12 months following June 30, 2018, an additional 26 percent in the 12 months thereafter, and the remaining 35 percent thereafter. We have elected to utilize the practical expedient of excluding contracts with an original duration of one year or less. As a result, the majority of our molecular information services contracts are excluded from the calculation and the balance is primarily comprised of transaction price associated with our long-term pharma research and development service contracts, as well as the molecular information platform program within the R&D Collaboration Agreement with Roche.

During the three and six months ended June 30, 2018, we recognized $1.7 million and $3.0 million, respectively, of revenue from performance obligations satisfied in prior periods, as a result of changes in the estimation of the transaction price for certain arrangements. Changes in the estimation of the transaction price for our clinical molecular information services revenue occur when we adjust our initial estimate based on actual cash collection experience from payors. Changes in the estimation of the transaction price for our pharma research and development services revenue occur based on revisions to our estimate of the constraint for variable consideration of performance-based milestones.